August 25, 2020 -- EpiVax has licensed its COVID-19 vaccine candidate, EPV-CoV-19, to EpiVax Therapeutics (EVT), formerly known as EpiVax Oncology.
EPV-CoV-19 is a peptide-based, epitope-driven vaccine that aims to drive a T cell-mediated immune response, creating a sort of "body armor" for users, according to the company.
Under the licensing agreement, EVT will use its vaccine platform and fundraising experience to advance EPV-CoV-19. The company is progressing to a clinical trial of the vaccine since it already received a positive preinvestigational new drug response from the U.S. Food and Drug Administration. Also, peptide production has started, and the investigational new drug application is being prepared.
Recently, EVT reorganized its executive team in preparation for the agreement and is raising $3 million to support the new program.